Clinically detected GISTs may be associated with widely different tumour mitotic counts and survival outcomes despite identical KIT mutations,3 suggesting that the GIST phenotype is influenced by molecular factors other than the primary KIT or PDGFRA mutation. This evidence concerns the gene PDGFRA and neoplasm.